GlassScriptPhysician profile
Chilka Rawal
NPI 1962656918
$9,865.28
in general payments reported to CMS, 2019-2025
37 companies · $2,156 in 2025
The $2,156 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,116 · 2022: $2,316 · 2023: $1,701 · 2024: $1,576 · 2025: $2,156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,332 · Education: $89.99 · Consulting Fee: $10.94.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,332.42 |
| Education | $89.99 |
| Consulting Fee | $10.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,910.88 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $1,424.87 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,062.86 | 2021-2025 | Dupixent |
| Csl Behring | $766.63 | 2021-2025 | Haegarda, Hizentra, Andembry |
| Optinose US, INC. | $617.09 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $541.38 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Astrazeneca Pharmaceuticals LP | $527.65 | 2021-2025 | Airsupra, Tezspire, Fasenra |
| Grifols USA, LLC | $463.86 | 2021-2025 | Xembify, Prolastin-C Liquid, Gamunex-C |
| Amgen INC. | $372.15 | 2021-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $367.88 | 2021-2025 | |
| Pfizer INC. | $342.38 | 2021-2025 | |
| Covis Pharma Gmbh | $195.58 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $170.91 | 2021-2025 | Orladeyo |
| Genentech USA, INC. | $169.80 | 2022-2025 | Xolair |
| Kaleo, INC. | $117.35 | 2022-2024 | Auvi-Q |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $103.63 | 2021-2025 | |
| Ionis Pharmaceuticals, INC. | $75.00 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $66.75 | 2021-2022 | |
| Lilly USA, LLC | $62.26 | 2025 | Ebglyss |
| Incyte Corporation | $60.14 | 2021-2022 | |
| Ars Pharmaceuticals Operations, INC. | $52.88 | 2025 | Neffy |
| Cycle Pharmaceuticals INC | $47.31 | 2025 | Sajazir |
| Blueprint Medicines Corporation | $41.12 | 2023-2024 | Ayvakit |
| Octapharma USA, INC. | $40.03 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $33.67 | 2023-2024 | Ryaltris |
| Pharming Healthcare, INC. | $32.27 | 2021-2024 | Ruconest |
| Leo Pharma INC. | $31.10 | 2022-2025 | Adbry |
| Merck Sharp & Dohme LLC | $29.11 | 2021-2023 | |
| Gc Biopharma USA, INC. | $25.77 | 2024-2025 | Alyglo, Alyglo |
| Organon LLC | $17.57 | 2025 | |
| Azurity Pharmaceuticals, INC. | $16.21 | 2025 | Alvesco |
| Aytu Biopharma, INC. | $14.55 | 2024 | Karbinal |
| Bio Products Laboratory USA, INC. | $14.08 | 2021 | |
| Alk-Abello, INC | $13.84 | 2021 | |
| Abbvie INC. | $13.78 | 2023 | |
| Uswm, LLC | $12.00 | 2021 | |
| Adma Biomanufacturing LLC | $10.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chilka Rawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.